1. Zhang D, Wang Z, Shang D, Yu J, Yuan S. Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study. Melanoma Res. 2019;29(1):77-84.
2. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164(4):776-84.
3. Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863-73.
4. Fattore L, Ruggiero CF, Liguoro D, Castaldo V, Catizone A, Ciliberto G, et al. The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma. Front Oncol. 2021;11:645069.
5. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF. Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaF<sup>V600E</sup> Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases. Journal of Pharmacology and Experimental Therapeutics. 2013;344(3):655-64.
6. Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacol Res. 2017;123:10-25.
7. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117-34.
8. National Cancer Institute. FDA approvals for cabozantinib. Accessed 09 December 2020 [Available from: https://www.cancer.gov/about-cancer/treatment/drugs/cabozantinib-s-malate.
9. Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, et al. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017;116(4):432-40.
10. Négrier S, Moriceau G, Attignon V, Haddad V, Pissaloux D, Guerin N, et al. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports. J Med Case Rep. 2018;12(1):351.
11. Sun TY, Niu X, Chakraborty A, Neal JW, Wakelee HA. Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2019;14(2):e21-e4.
12. Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, et al. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-oncology. 2018;20(2):249-58.
13. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298-308.
14. Bischof K, Knappskog S, Hjelle SM, Stefansson I, Woie K, Salvesen HB, et al. Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers. Scientific Reports. 2019;9(1):5244.
15. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, et al. Cell Viability Assays. In: Markossian S, Sittampalam GS, Grossman A, Brimacombe K, Arkin M, Auld D, et al., editors. Assay Guidance Manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004.
16. Shang R, Song X, Wang P, Zhou Y, Lu X, Wang J, et al. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut. 2020.
17. Dong Y, Hu H, Sun Y, Qin M, Gong P, Hou Y, et al. Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors. Bioorganic & medicinal chemistry letters. 2020;30(23):127610.
18. Starenki D, Sosonkina N, Hong SK, Lloyd RV, Park JI. Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells. Int J Mol Sci. 2019;20(9).
19. Zhang L, Scorsone K, Woodfield SE, Zage PE. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer chemotherapy and pharmacology. 2015;76(5):977-87.
20. Duval K, Grover H, Han L-H, Mou Y, Pegoraro AF, Fredberg J, et al. Modeling Physiological Events in 2D vs. 3D Cell Culture. Physiology (Bethesda). 2017;32(4):266-77.
21. Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK, et al. The soft agar colony formation assay. J Vis Exp. 2014(92):e51998.
22. Sundstrøm T, Prestegarden L, Azuaje F, Aasen SN, Røsland GV, Varughese JK, et al. Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis. Acta Neuropathol Commun. 2019;7(1):55.
23. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135(6):807-10.
24. Xiang Q, Chen W, Ren M, Wang J, Zhang H, Deng DY, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014;20(11):2959-70.
25. Broussard L, Howland A, Ryu S, Song K, Norris D, Armstrong CA, et al. Melanoma Cell Death Mechanisms. Chonnam Med J. 2018;54(3):135-42.
26. Cavalcante GC, Schaan AP, Cabral GF, Santana-da-Silva MN, Pinto P, Vidal AF, et al. A Cell's Fate: An Overview of the Molecular Biology and Genetics of Apoptosis. Int J Mol Sci. 2019;20(17).
27. Qian C, Wu Z, Ng RC, Garcia-Barceló MM, Yuan ZW, Wong KKY, et al. Conditional deletion of platelet derived growth factor receptor alpha (Pdgfra) in urorectal mesenchyme causes mesenchyme apoptosis and urorectal developmental anomalies in mice. Cell Death Differ. 2019;26(8):1396-410.
28. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev. 2006;17(4):305-23.
29. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature. 2001;411(6834):207-11.
30. Assent D, Bourgot I, Hennuy B, Geurts P, Noël A, Foidart JM, et al. A membrane-type-1 matrix metalloproteinase (MT1-MMP)-discoidin domain receptor 1 axis regulates collagen-induced apoptosis in breast cancer cells. PloS one. 2015;10(3):e0116006.
31. Willenberg A, Saalbach A, Simon JC, Anderegg U. Melanoma cells control HA synthesis in peritumoral fibroblasts via PDGF-AA and PDGF-CC: impact on melanoma cell proliferation. J Invest Dermatol. 2012;132(2):385-93.
32. Wang J, Sinnberg T, Niessner H, Dölker R, Sauer B, Kempf WE, et al. PTEN regulates IGF-1R-mediated therapy resistance in melanoma. Pigment Cell Melanoma Res. 2015;28(5):572-89.
33. Kelley RK, J WO, Hazra S, Benzaghou F, Yau T, Cheng AL, et al. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncol. 2020;16(21):1525-36.
34. Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest. 2013;123(5):2257-67.
35. Tworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res. 2013;26(4):527-41.
36. Fukunaga-Kalabis M, Martinez G, Liu ZJ, Kalabis J, Mrass P, Weninger W, et al. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol. 2006;175(4):563-9.
37. Reger de Moura C, Battistella M, Sohail A, Caudron A, Feugeas JP, Podgorniak MP, et al. Discoidin domain receptors: A promising target in melanoma. Pigment Cell Melanoma Res. 2019;32(5):697-707.
38. Romayor I, Badiola I, Olaso E. Inhibition of DDR1 reduces invasive features of human A375 melanoma, HT29 colon carcinoma and SK-HEP hepatoma cells. Cell Adh Migr. 2020;14(1):69-81.
39. Vaishampayan UN, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, Dobson KC, Boerner J, et al. Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(2):652-62.
40. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene. 2007;26(22):3113-21.
41. Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy. Molecular cancer. 2018;17(1):37.
42. Devji T, Levine O, Neupane B, Beyene J, Xie F. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Oncol. 2017;3(3):366-73.
43. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(7):1473-82.
44. Yang S, Zhang X, Qu H, Qu B, Yin X, Zhao H. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway. Cancer Gene Ther. 2020;27(5):368-77.
45. Gajos-Michniewicz A, Czyz M. WNT Signaling in Melanoma. Int J Mol Sci. 2020;21(14).
46. Jeong WJ, Ro EJ, Choi KY. Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway. NPJ Precis Oncol. 2018;2(1):5.
47. Bergström JD, Westermark B, Heldin NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res. 2000;259(1):293-9.
48. Janssen J. New Insights from IGF-IR Stimulating Activity Analyses: Pathological Considerations. Cells. 2020;9(4).
49. Vella V, Malaguarnera R, Nicolosi ML, Morrione A, Belfiore A. Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection. Biochim Biophys Acta Mol Cell Res. 2019;1866(11):118522.
50. Malaguarnera R, Nicolosi ML, Sacco A, Morcavallo A, Vella V, Voci C, et al. Novel cross talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses. Oncotarget. 2015;6(18):16084-105.